IMVT - CIK 0001764013
The table below shows Immunovant, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $15.44M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $17.51M |
| $26.02M |
| $19.78M |
| $18.47M |
| $18.81M |
| Operating income | - | - | - | - | - | - |
| Income tax | $1.55M | $594.00K | $913.00K | $152.00K | $78.00K | $77.00K |
| Net income | -$110.64M | -$126.50M | -$120.61M | -$111.12M | -$109.12M | -$87.15M |
| EPS (diluted) | -$0.61 | -$0.73 | -$0.71 | -$0.76 | -$0.74 | -$0.60 |